Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200-Day Moving Average - Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.54. Xtant Medical shares last traded at $0.54, with a volume of 91,934 shares changing hands.

Xtant Medical Price Performance

The company has a market cap of $66.72 million, a P/E ratio of -3.69 and a beta of 0.35. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. The stock has a 50-day simple moving average of $0.54.

Hedge Funds Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC lifted its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 70.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 515,006 shares of the medical device company's stock after acquiring an additional 212,394 shares during the quarter. Geode Capital Management LLC owned approximately 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. 69.33% of the stock is owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

Remove Ads